4.5 Review

The emerging role of dipeptidyl-peptidase-4 as a therapeutic target in lung disease

Journal

EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 24, Issue 2, Pages 147-153

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/14728222.2020.1721468

Keywords

Asthma; chronic obstructive pulmonary disease (COPD); cluster of differentiation 26 (CD26); dipeptidyl-peptidase-4 (DPP-4)

Ask authors/readers for more resources

Introduction: Dipeptidyl-peptidase-4 (DPP-4) is a surface bound ectopeptidase that is commonly known as CD26 or adenosine deaminase binding protein. DPP-4 is membrane anchored but it can be cleaved by numerous proteases including matrix-metalloproteinases (MMPs). DPP-4 is expressed by endothelial and epithelial cells, the kidney, intestine and cells of the immune system; it has a broad spectrum of biological functions in immune regulation, cancer biology and glucose metabolism. Areas covered: This article sheds light on the functions of DPP-4, the molecular mechanisms that govern its expression, it's role in the pathogenesis of common respiratory illnesses and potential as a therapeutic target. Expert opinion: DPP-4 has a deleterious role in respiratory disease. Its biological functions, key molecular pathways, interactions and associations are slowly being elucidated. Progressing our knowledge of the role of this multi-faceted molecule may yield vital and novel therapies for respiratory diseases such as lung cancer, asthma, and chronic obstructive pulmonary disease (COPD).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available